Skip to content

A randomized, double-blind controlled clinical study of cyclopofol for comfort treatment of patients with painless gastroscopy

A randomized, double-blind controlled clinical study of cyclopofol for comfort treatment of patients with painless gastroscopy

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200066323
Enrollment
Unknown
Registered
2022-12-01
Start date
2022-12-03
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless gastroscope

Interventions

Group P:propofol
Group H:cyclopofol
Group PE:Propofol and etomidate
Group HE:Cyclopofol + etomidate

Sponsors

Jiangxi Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: The patient must meet all of the following options simultaneously: 1. The patient should be aged 18-65 years old, regardless of gender, and have a Body Mass Index (BMI) of 18-30 kg/m2. 2. The surgery patients choose to the American Society of anesthesiologists (American Society of Anesthesiologistsphysical status, ASA) class I - II patients 3. Patients requiring painless gastroscopy 4. The time of gastroscopy is expected to be less than 30 minutes 5. Subjects participated in this experiment voluntarily and signed informed consent If the answer to any of the above questions is "no", the case will not be included in the study

Exclusion criteria

Exclusion criteria: Any one of the following situations is not included in this experiment: 1) Without an escort or guardian; 2) People with abnormal hearing and vision cannot communicate; 3) A history of mental illness or long-term use of psychotropic drugs or chronic sedative drugs; 4) Neuromuscular diseases; 5) Uncontrolled severe hypertension, severe arrhythmia, unstable angina pectoris; 6) Acute respiratory tract infection, asthma attack, difficult airway; 7) Liver dysfunction (Child-Pugh grade C or above), acute upper gastrointestinal bleeding shock, gastrointestinal perforation; 8) Severe renal dysfunction (Cr clearance rate <30ml/min); 9) Allergic to drugs or other contraindications; 10) Participating in another drug clinical trial within the past 30 days; 11) Other conditions deemed unsuitable for inclusion by the researcher.

Design outcomes

Primary

MeasureTime frame
Pain of injection;dream;Blood pressure;

Countries

china

Contacts

Public Contactzhang ming sheng

Jiangxi Provincial People's Hospital

zms9201@126.com13807915056

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026